Sequential homoharringtonine (HHT) and interferon (IFN-A) produce high hematologic and cytogenetic response rates in Philadelphia chromosome positive (Ph) chronic myelogenous leukemia (CML).

被引：0
|
作者：
O'Brien, S
Kantarjian, H
Koller, C
Andreeff, M
Feldman, E
Keating, M
Beran, M
Freireich, E
Rios, MB
Talpaz, M
机构：
来源：
BLOOD | 1998年 / 92卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2707
引用
收藏
页码：656A / 656A
页数：1
相关论文
共 50 条
  • [21] RESPONSE AND TOXICITY TO ALPHA-INTERFERON IN CHILDHOOD PHILADELPHIA-CHROMOSOME POSITIVE (PH+) CHRONIC MYELOCYTIC-LEUKEMIA (CML)
    DOW, LW
    CULBERT, SJ
    KENNEDY, W
    PINKEL, DP
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1988, 29 : 224 - 224
  • [22] Unmaintained complete remissions (cures) among interferon treated Philadelphia positive chronic myelogenous leukemia (CML Ph1) patients
    Talpaz, M
    Kurzrock, R
    O'Brien, S
    Kantarjian, H
    BLOOD, 1998, 92 (10) : 317A - 317A
  • [23] A pilot study of all-trans retinoic acid (ATRA) in patients with Philadelphia chromosome (Ph)-positive chronic myelogenous leukemia (CML).
    Cortes, J
    Kantarjian, H
    OBrien, S
    Beran, M
    Estey, E
    Keating, M
    Talpaz, M
    BLOOD, 1996, 88 (10) : 3515 - 3515
  • [24] Imatinib in Philadelphia chromosome-positive chronic phase CML patients: Molecular and cytogenetic response rates and prediction of clinical outcome
    le Coutre, P
    Kreuzer, KA
    Na, IK
    Schwarz, M
    Lupberger, J
    Holdhoff, M
    Baskaynak, G
    Gschaidmeier, H
    Platzbecker, U
    Ehninger, G
    Prejzner, W
    Huhn, D
    Schmidt, CA
    AMERICAN JOURNAL OF HEMATOLOGY, 2003, 73 (04) : 249 - 255
  • [25] Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia
    Drummond, MW
    Holyoake, TL
    CANCER, 2003, 98 (08) : 1776 - 1777
  • [26] Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia
    Kantarjian, H
    Talpaz, M
    O'Brien, S
    Giles, F
    Rios, MB
    White, K
    Garcia-Manero, G
    Ferrajoli, A
    Verstovsek, S
    Wierda, W
    Kornblau, S
    Cortes, J
    CANCER, 2003, 97 (09) : 2225 - 2228
  • [27] INTERFERON ALFA-2C IN CHRONIC MYELOGENOUS LEUKEMIA (CML) - HEMATOLOGIC, CYTOGENETIC AND MOLECULAR-GENETIC RESPONSE OF PATIENTS WITH CHRONIC PHASE CML PREVIOUSLY RESISTANT TO THERAPY WITH INTERFERON-GAMMA
    HERRMANN, F
    JONAS, D
    HELFRICH, SG
    LINDEMANN, A
    SCHLEIERMACHER, E
    MERTELSMANN, R
    BLUT, 1990, 61 (04): : 226 - 231
  • [28] INDUCTION OF TRUE REMISSION IN PHILADELPHIA-CHROMOSOME POSITIVE (PH1+) CHRONIC MYELOGENOUS LEUKEMIA (CML) WITH THE L15 PROTOCOL
    ARLIN, Z
    KEMPIN, S
    GEE, T
    GOTO, T
    CHAGANTI, R
    KOENIGSBERG, E
    CLARKSON, B
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1979, 20 (MAR): : 339 - 339
  • [29] ALPHA-INTERFERON (IFN) RESULTS IN HIGH COMPLETE CYTOGENETIC RESPONSE RATE IN PATIENTS WITH CYTOGENETIC-ONLY RELAPSE OF CHRONIC MYELOGENOUS LEUKEMIA (CML) AFTER MARROW TRANSPLANTATION (BMT)
    HIGANO, C
    RASKIND, W
    FLOWERS, M
    BLOOD, 1993, 82 (10) : A169 - A169
  • [30] CLINICAL AND PROGNOSTIC FEATURES OF PATIENTS WITH PHILADELPHIA-CHROMOSOME (PH1) POSITIVE CHRONIC MYELOGENOUS LEUKEMIA (CML) AND EXTRAMEDULLARY DISEASE (EMD)
    TERJANIAN, T
    KANTARJIAN, H
    KEATING, M
    MCCREDIE, K
    WALTERS, R
    FREIREICH, E
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1986, 27 : 193 - 193
12345